REDWOOD CITY, Calif., Sept. 25, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be presenting at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2018 Healthcare Conference. At these events, AcelRx management will provide an overview of the business and company updates during the live presentations and will be available for one-on-one meetings with investors.
Details of the events are as follows:
Cantor Fitzgerald Global Healthcare Conference
Date: Monday, October 1, 2018
Location: Intercontinental New York Barclay Hotel, New York City
Presentation Time: 9:30 am ET
Ladenburg Thalmann 2018 Healthcare Conference
Date: Tuesday, October 2, 2018
Location: Sofitel New York, New York City
Presentation Time/Place: 8:30 am ET
Both the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2018 Healthcare Conference will be webcast live and can be accessed through the Investors page at www.acelrx.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has two product candidates in the United States including DSUVIA™ (sufentanil sublingual tablet, 30 mcg), with a proposed indication for the treatment of moderate-to-severe acute pain in medically supervised settings, and Zalviso® (sufentanil sublingual tablet system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in hospitalized patients. DZUVEO™, as DSUVIA is known in Europe, and Zalviso are both approved products in Europe.
For additional information about AcelRx, please visit www.acelrx.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-in-october-300718769.html
SOURCE AcelRx Pharmaceuticals, Inc.
Brian Korb, Solebury Trout, 646-378-2923, email@example.com; Raffi Asadorian, Chief Financial Officer, AcelRx, firstname.lastname@example.org